Mumbai, July 9 -- Under the terms of the agreement, Lupin will be responsible for the development, manufacturing, and supply of the product within the agreed territories. Zentiva will handle commercialization activities across Europe and the CIS markets, leveraging its extensive commercial infrastructure and regulatory expertise in the region. Lupin will retain commercialization rights in other regions, including the USA and Canada.

As part of the deal, Zentiva will make a non-refundable payment of up to USD 50 million, tied to regulatory milestones. This includes an upfront payment of $10 million upon execution of the agreement. Both companies will jointly invest in the development of the biosimilar, and profits from defined markets wil...